SIRT6 has increasingly been recognized as a promising therapeutic target in pancreatic cancer, particularly due to its multifaceted role in modulating tumorigenesis, angiogenesis and responses to chemotherapy. Here, SIRT6 is linked to pancreatic neoplasm.